Johnson & Johnson Gets EU Approval for IMAAVY to Treat Generalized MG
Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive Johnson & Johnson announced that...